<DOC>
	<DOCNO>NCT00330668</DOCNO>
	<brief_summary>This extension study Tercica study MS301 ( NCT00125164 ) intend collect long term safety efficacy data continue use recombinant human insulin-like growth factor-1 ( rh IGF-1 ) child adolescent treat primary IGF-1 deficiency ( IGFD ) . The secondary objective use data collect learn relationship IGF-1 exposure promotion normal growth pubertal development .</brief_summary>
	<brief_title>Treatment Children Adolescents With Growth Failure Associated With Primary IGF-1 Deficiency</brief_title>
	<detailed_description>Primary IGFD term use describe patient intrinsic cellular defect GH action . In protocol , subject complete one year mecasermin treatment Tercica protocol MS301 ( NCT00125164 ) allow enroll extension study . All subject plan receive treatment . This Phase IIIb open-label , multi-center , parallel dose , extension study conduct approximately 40 center across United States .</detailed_description>
	<mesh_term>Growth Disorders</mesh_term>
	<mesh_term>Failure Thrive</mesh_term>
	<criteria>Parents legally authorize representative must give sign informed consent trial related activity conduct Where require , assent subject appropriately document prior study related activity Completion assessment Visit 9 ( Month 120 Study MS301 [ NCT00125164 ] ) Incomplete participation MS301 ( NCT00125164 ) Known suspect allergy trial product ( mecasermin , recombinant human IGF1 injection ) formulation Development presence chronic condition except approve Medical Monitor Pregnancy Any social medical condition , opinion investigator , would detrimental either subject study</criteria>
	<gender>All</gender>
	<minimum_age>4 Years</minimum_age>
	<maximum_age>15 Years</maximum_age>
	<verification_date>May 2011</verification_date>
	<keyword>Insulin-like Growth Factor Deficiency</keyword>
	<keyword>IGF-1</keyword>
	<keyword>Short Stature</keyword>
</DOC>